148 related articles for article (PubMed ID: 36358614)
1. Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy.
Wikström P; Bergström SH; Josefsson A; Semenas J; Nordstrand A; Thysell E; Crnalic S; Widmark A; Karlsson CT; Bergh A
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358614
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.
Thysell E; Vidman L; Ylitalo EB; Jernberg E; Crnalic S; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Widmark A; Rydén P; Bergh A; Wikström P
Mol Oncol; 2019 Aug; 13(8):1763-1777. PubMed ID: 31162796
[TBL] [Abstract][Full Text] [Related]
3. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.
Ylitalo EB; Thysell E; Landfors M; Brattsand M; Jernberg E; Crnalic S; Widmark A; Hultdin M; Bergh A; Degerman S; Wikström P
Clin Epigenetics; 2021 Jun; 13(1):133. PubMed ID: 34193246
[TBL] [Abstract][Full Text] [Related]
4. A Novel Radiographic Pattern Related to Poor Prognosis in Patients with Prostate Cancer with Metastatic Spinal Cord Compression.
Wänman J; Abul-Kasim K; Semenas J; Thysell E; Bergh A; Wikström P; Crnalic S
Eur Urol Open Sci; 2023 Feb; 48():44-53. PubMed ID: 36743403
[TBL] [Abstract][Full Text] [Related]
5. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
Thysell E; Köhn L; Semenas J; Järemo H; Freyhult E; Lundholm M; Thellenberg Karlsson C; Damber JE; Widmark A; Crnalic S; Josefsson A; Welén K; Nilsson RJA; Bergh A; Wikström P
Mol Oncol; 2022 Feb; 16(4):846-859. PubMed ID: 34889043
[TBL] [Abstract][Full Text] [Related]
7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
8. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes.
Dudka I; Lundquist K; Wikström P; Bergh A; Gröbner G
J Transl Med; 2023 Nov; 21(1):860. PubMed ID: 38012666
[TBL] [Abstract][Full Text] [Related]
10. Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer.
Sharma NV; Pellegrini KL; Ouellet V; Giuste FO; Ramalingam S; Watanabe K; Adam-Granger E; Fossouo L; You S; Freeman MR; Vertino P; Conneely K; Osunkoya AO; Trudel D; Mes-Masson AM; Petros JA; Saad F; Moreno CS
Cancers (Basel); 2018 Oct; 10(10):. PubMed ID: 30314329
[TBL] [Abstract][Full Text] [Related]
11. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.
Li H; Zhang Y; Li D; Ma X; Xu K; Ding B; Li H; Wang Z; Ouyang W; Long G; Zeng J; Liu H; Yan L; Zhang Y; Liu Z; Guan W; Hu Z; Liu C; Wan J; Wang G; Pu X; Zhang M; Guo L; An R; Qi J; Guo A; Ye Z; Liu J; Zhang X; Xu H
Eur Urol; 2021 Jun; 79(6):879-886. PubMed ID: 33579577
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
16. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
Feng FY; Thomas S; Saad F; Gormley M; Yu MK; Ricci DS; Rooney B; Brookman-May S; McCarthy S; Olmos D; Chowdhury S; Hadaschik B; Liu Y; Davicioni E; Smith MR; Small EJ
JAMA Oncol; 2021 Jul; 7(7):1005-1014. PubMed ID: 34081076
[TBL] [Abstract][Full Text] [Related]
17. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
Han H; Lee HH; Choi K; Moon YJ; Heo JE; Ham WS; Jang WS; Rha KH; Cho NH; Giancotti FG; Choi YD
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1080-1092. PubMed ID: 33903734
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor is a tumor suppressor and proliferator in prostate cancer.
Niu Y; Altuwaijri S; Lai KP; Wu CT; Ricke WA; Messing EM; Yao J; Yeh S; Chang C
Proc Natl Acad Sci U S A; 2008 Aug; 105(34):12182-7. PubMed ID: 18723679
[TBL] [Abstract][Full Text] [Related]
19. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
20. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
